Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:42 04/07/2024 BST			5-day change	1st Jan Change
243.4 ^CHF	-1.06%		-2.48%	-0.45%

07-04	Swiss Equities Close Higher as Inflation Eases; Roche Slumps	MT
07-04	Market Update-Europe closes higher on optimism about US rates	RE

ROCHE HOLDINGS AG : Barclays remains Neutral

January 09, 2024 at 01:28 pm

Barclays analyst Emily Field maintains his Neutral opinion on the stock. The target price is unchanged at CHF 260.

Latest news about Roche Holding AG

Swiss Equities Close Higher as Inflation Eases; Roche Slumps	07-04	MT
Market Update-Europe closes higher on optimism about US rates	07-04	RE
ROCHE HOLDINGS AG : Gets a Sell rating from Goldman Sachs	07-04	ZD
Market Update-European stock markets rise in absence of Wall Street	07-04	RE
ROCHE HOLDINGS AG : UBS sticks Neutral	07-04	ZD
Dax starts trading firmer - US interest rate policy in focus	07-04	RE
ROCHE HOLDINGS AG : Sell rating from JP Morgan	07-04	ZD
European shares advance on rate optimism; UK elections in focus	07-04	RE
Roche: study in lung cancer fails and is discontinued	07-04	CF
Roche to halt trial in latest setback for new cancer drug	07-04	RE
Roche to Halt Lung Cancer Trial After Results Miss Goals	07-04	DJ
Roche to Halt Trial of Combination Formulation for Non-small Cell Lung Cancer Treatment	07-04	MT
Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer	07-04	CI
ROCHE HOLDINGS AG : Berenberg sticks Neutral	07-03	ZD
Goldman Sachs Lowers Price Target on Roche, Maintains Sell Recommendation	07-02	MT
ROCHE HOLDINGS AG : Jefferies reiterates its Neutral rating	07-02	ZD
ROCHE HOLDINGS AG : Goldman Sachs reiterates its Sell rating	07-02	ZD
'HB': Sanofi plans to invest billions in Frankfurt	07-01	DP
ROCHE HOLDINGS AG : Deutsche Bank remains Neutral	07-01	ZD
BioPharma Credit to Provide Additional Funding to LumiraDx Amid Roche Deal	07-01	MT
Swiss Market Index Closes Little Changed Amid Key European Inflation Data	06-28	MT
Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication	06-28	MT
Roche: positive CHMP opinion for Vabysmo in OVR	06-28	CF
Roche: positive CHMP opinion for PiaSky in HPN	06-28	CF
Roche Gets EU Panel's Backing for Rare Blood Disorder Therapy	06-28	MT

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

23/07/2024 - American Society of Retina Specialists Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : In line quarterly results won’t cut it for Roche

April 24, 2024 at 04:50 pm

Obesity: Roche joins the battle

December 04, 2023 at 03:48 pm

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

246 CHF

Average target price

276.4 CHF

Spread / Average Target

+12.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-0.45%	221B
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+38.95%	621B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.21%	238B
NOVARTIS AG	+14.58%	218B
AMGEN INC.	+7.42%	166B
PFIZER, INC.	-3.79%	157B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : Barclays remains Neutral

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals